SG193630A1 - Markers for identifying tumor cells, methods and kit thereof - Google Patents

Markers for identifying tumor cells, methods and kit thereof Download PDF

Info

Publication number
SG193630A1
SG193630A1 SG2013072483A SG2013072483A SG193630A1 SG 193630 A1 SG193630 A1 SG 193630A1 SG 2013072483 A SG2013072483 A SG 2013072483A SG 2013072483 A SG2013072483 A SG 2013072483A SG 193630 A1 SG193630 A1 SG 193630A1
Authority
SG
Singapore
Prior art keywords
cancer
combination
group
cells
prognosis
Prior art date
Application number
SG2013072483A
Other languages
English (en)
Inventor
Manjiri Bakre
Original Assignee
Oncostem Diagnostics Mauritius Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncostem Diagnostics Mauritius Pvt Ltd filed Critical Oncostem Diagnostics Mauritius Pvt Ltd
Publication of SG193630A1 publication Critical patent/SG193630A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
SG2013072483A 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof SG193630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2835CH2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (1)

Publication Number Publication Date
SG193630A1 true SG193630A1 (en) 2013-10-30

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013072483A SG193630A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Country Status (8)

Country Link
US (2) US8772455B2 (https=)
EP (1) EP2691776A4 (https=)
JP (1) JP2014515821A (https=)
KR (1) KR101621036B1 (https=)
CN (1) CN103562723B (https=)
AU (1) AU2012235767B2 (https=)
SG (1) SG193630A1 (https=)
WO (1) WO2012131564A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968542B1 (en) * 2013-03-15 2021-06-23 Varian Medical Systems, Inc. Biomarkers for radiation treatment
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
US10900968B2 (en) * 2016-05-24 2021-01-26 Oncostem Pte. Ltd. Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723257B1 (en) * 2004-02-23 2019-01-09 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
UA110315C2 (uk) * 2006-09-29 2015-12-25 Oncomed Pharm Inc Композиція та спосіб лікування раку
US7968169B2 (en) * 2007-08-07 2011-06-28 The Boeing Company Compound contoured composite beams and fabrication methods
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
JPWO2011007853A1 (ja) * 2009-07-14 2012-12-27 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体
US20130059903A1 (en) * 2010-03-12 2013-03-07 The Johns Hopkins University Compositions and Methods for Characterizing Breast Cancer

Also Published As

Publication number Publication date
KR101621036B1 (ko) 2016-05-13
US8772455B2 (en) 2014-07-08
US20140295459A1 (en) 2014-10-02
AU2012235767B2 (en) 2016-02-04
EP2691776A1 (en) 2014-02-05
AU2012235767A1 (en) 2013-11-07
WO2012131564A1 (en) 2012-10-04
JP2014515821A (ja) 2014-07-03
CN103562723A (zh) 2014-02-05
US20120244556A1 (en) 2012-09-27
CN103562723B (zh) 2017-04-26
EP2691776A4 (en) 2015-04-15
KR20140015500A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
SG193630A1 (en) Markers for identifying tumor cells, methods and kit thereof
Civenni et al. Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer
Su et al. Kibra and Merlin activate the Hippo pathway spatially distinct from and independent of expanded
Song et al. Specific interaction of KIF11 with ZBP1 regulates the transport of β-actin mRNA and cell motility
Kong et al. Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair
Zhang et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases
US20090081237A1 (en) Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
Eguether et al. Intraflagellar transport is deeply integrated in hedgehog signaling
Kosar et al. The human nucleoporin Tpr protects cells from RNA-mediated replication stress
Li et al. YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
Wang et al. Connexin43 increases the sensitivity of prostate cancer cells to TNFα-induced apoptosis
Kleinschmidt et al. Rgnef promotes ovarian tumor progression and confers protection from oxidative stress
Segala et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling
Mazaira et al. Nucleocytoplasmic shuttling of the glucocorticoid receptor is influenced by tetratricopeptide repeat-containing proteins
Patel et al. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression
Zhao et al. RST1 is a FREE1 suppressor that negatively regulates vacuolar trafficking in Arabidopsis
Jensen et al. Disruption of the extracellular matrix progressively impairs central nervous system vascular maturation downstream of β-catenin signaling
Sun et al. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma
Radu et al. Cajal‐type cells from human mammary gland stroma: phenotype characteristics in cell culture
Bolinger et al. Occludin S471 phosphorylation contributes to epithelial monolayer maturation
Tischler et al. FLIP (C1orf112)-FIGNL1 complex regulates RAD51 chromatin association to promote viability after replication stress
van Zon et al. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression
Faktorová et al. Functional differentiation of Sec13 paralogues in the euglenozoan protists
Harper et al. RNA Pol II inhibition activates cell death independently from the loss of transcription
Lu et al. Zebrafish TMEM47 is an effective blocker of IFN production during RNA and DNA virus infection